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Summary
Vascular endothelium activated by endotoxin (lipopolysaccharide [LPS]) and cytokines plays an
important role in organ inflammation and blood leukocyte recruitment observed during sepsis.
Endothelial cells can be activated by LPS directly, afterits interaction with LPS-binding protein
and soluble CD14 in plasma. LPS-LPS-binding protein complexes in blood also interact with
monocytes and neutrophils bearing glycosyl-phosphatidylinositol (GPI) anchored membrane CD14
(mCD14), promoting the release of cytokines such as tumor necrosis factor and interleukin 1
(IL-1). These molecules, in turn, have the capacity to activate endothelial cells providing an indirect
pathway for LPS-dependent endothelial cell activation. In this work, we address the relative
importance of the direct and the indirect pathway of in vitro LPS-induced human umbilical vein
endothelial cell (HUVEC) activation. Substituting whole blood for plasma resulted in a 1,000-
fold enhancement of HUVEC sensitivity to LPS. Both blood- and plasma-dependent enhanced
activationof HUVEC were blocked with an anti-CD14 monoclonal antibody. Blood from patients
with paroxysmal nocturnal hemoglobinuria, whose cells lack mCD14 and other GPI anchored
proteins, was unable to enhance LPS activation ofHUVEC above the level observed with plasma
alone. IL-10, an inhibitor of monocyte release of cytokines, decreased the blood-dependent
enhancement of HUVEC activation by LPS. Blood adapted to small doses of LPS was also less
efficient than nonadapted blood in producing this enhancement. Addition ofpurified mononuclear
cells to HUVEC or the transfer of plasma from whole blood incubated with LPS to HUVEC,
duplicated the enhancement effect observed when whole blood was incubated with HUVEC.
Taken together, these data suggest that the indirect pathway of LPS activation of endothelial
cell is mediated by monocytes and mCD14 through the secretion of a soluble mediator(s). The
indirect pathway is far more efficient than the direct, plasma-dependent pathway.
~/
Vascular endothelium activated by proinflammatory mol-
ecules actively participates in organ inflammation by
secreting cytokines, chemokines, and leukocyte adhesion mol-
ecules (1). Vascular endothelium is therefore thought to play
an important role in the pathogenesis of multiple organ dys-
function such as is observed during sepsis.
Endotoxin, or LPS, has been recognized as a major trigger
for host inflammatory responses seen during Gram-negative
sepsis (2). Either LPS or Gram-negative bacteria can repro-
duce the clinical syndrome known as sepsis (2). Two glyco-
proteins are clearly implicated in the molecular and cellular
basis of these events. The first, LPS-binding protein (LBP),'
1 Abbreviations used in this paper: GPI, glycosyl-phosphotidylinositol ;
HUVEC, humanumbilicalvein endothelialcell; LBP, LPS-binding protein;
mCD14, membrane-bound CD14; PNH, paroxysmal nocturnal hemo-
globinuria; sCD14, solubleform of CD14; VCAM, vascular cell adhesion
molecule 1.
present in normal serum, recognizes and binds LPS with high
affinity through its lipid A moiety (3). LPS-LBP complexes
then activate myeloid cells through the second glycoprotein,
membrane-bound CD14 (mCD14), to produce cytokines such
as TNF and IL-1(3 (4, 5).
LPS also induces endothelial cell responses, but through
two different pathways. The direct pathway, which is serum
dependent, requires the interaction of LPS with LBP and the
soluble form of CD14 (sCD14), present in human serum at
concentrations of 2-5 jig/ml. LPS-sCD14 complexes interact
with an as yet unknown receptor on the endothelial cell sur-
face in order to trigger cell responses (6). The same pathway
of LPS activation has been described for some epithelial cell
lines (6). Endothelial and epithelial cells apparently do not
express mCD14 (6, 7). As mentioned above, LPS in the blood
stream triggers the release of numerous cytokines and other
proinflammatory molecules by white blood cells. Some of
them, such as TNF and IL-1, have a proinflammatory effect
on endothelial cells, independently of LPS (8). This is re-
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cell activation. Once activated, endothelial cells secrete cyto-
kines (IL-1,3, IL-6), chemokines (typically IL-8), andupregu-
late various adhesion molecules for leukocytes such as vas-
cular cell adhesions, molecule 1 (VCAM-1), intercellular
adhesion molecule 1 (ICAM-1) and selectins (8, 9).
In this work, the relative importance of the direct versus
the indirect pathway for endothelial cell activation by LPS
in vitro was studied. We show that the presence of blood
cells will amplify the endothelial cell response to LPS by a
factor of 1,000 compared with plasma alone. This enhance-
ment is blocked by mAbs which block mCD14 and sCD14
function. Furthermore, blood from paroxysmal nocturnal
hemoglobinuria (PNH) patients, whose white cells lack all
glycosyl-phosphatidylinositol (GPI) anchored proteins in-
cluding CD14, does not amplify the endothelial response to
LPS. Becausepurified mononuclearcellsor plasma from blood
incubated with LPS replaced whole blood, we suggest that
it is the monocyte which serves as the source of a soluble
mediator(s) acting as agonist(s) for theindirect activation of
endothelial cells by LPS.
Materials and Methods
Cells.
￿
Humanumbilicalvein endothelial cells (HUVEC) were
obtained, identified as described (10), and maintained using 199
medium (BioWhittaker, Inc., Walkersville, MD) supplemented with
20% fetal bovine serum (HyClone Laboratories, Logan, UT), 90
pglml heparin (Sigma Chemical Co., St. Louis, MO) (11) and 30
lAg/ml endothelialcellgrowth supplement (UBI, Lake Placid, NY)
(12). Second to fourth passages were used for the assays.
Reagents.
￿
Escherichia coli 0111:B4andSalmonella minnesota wild-
type LPS were obtained from List Biological Laboratories (Camp-
bell, CA). Re595LPSwas produced as described (13). Heat-killed
Staphylococcus aureus was a gift from T Kirkland (University of
California at San Diego, San Diego, CA). Recombinant human
IL10 (MW0) and a rat anti-hIL10 mAb were kindly provided by
Dr. K. Moore, DNAX (Palo Alto, CA). The anti-CD14 mAbs
used were 28C5 and 18E12 (gift of D. Leturcq and A. Moriarty,
R.WJohnson Pharmaceutical Research Institute, SanDiego, CA);
MY4, MY4-RD1, and isotype control (Coulter Corp., Hialeah,
FL); UCHMI (Sera-Lab, Accurate Chemical & Scientific Corp.,
Westbury, NY); and 63D3 (American Type Culture Collection,
Rockville, MD). Anti-CD18 mAb IB4 was a gift from K. Arfors
(Medical BiologyInstitute, LaJolla, CA);FITC-labeled anti-CD11b
mAbanditsisotypecontrol were purchasedfrom Amac Inc. (West-
brook, ME); anti-hVCAM-1 mAb from R&D Systems (Min-
neapolis, MN); andperoxidase-conjugated goat anti-mouse IgGAb
from Cappel Laboratories (Durham, NC). IL8 levels in supernatants
were measured using commercial ELISA kits (R&D Systems).
Recombinant human TNF-ct was obtained from Cetus Corp.
(Emeryville, CA).
Blood.
￿
Normal humanbloodwas obtained from several healthy
individuals by venipuncture usingpyrogen-free syringes andneedles.
The blood was anticoagulated with 0.2% EDTA (Vacutainere,
Baxter, Irvine, CA) for FACS® studies or with 10 U/ml heparin
(Lymphomed, Deerfield, FL) for functional assays, and assayed
within 1 h after sampling. Plasma wasobtained by centrifugation
of beparinized blood. Purified neutrophils and mononuclear cells
from normal human blood were obtained using a standard Ficoll-
Paquedensity gradient as describedelsewhere(14). Analysis by stan-
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dard microscopy revealed that each cell population was>95% pure.
Blood from twopatients with PNH was obtained and treated the
same wayas normal humanblood. Abloodprofile, includingblood
smear and cell counts, was obtained on the day of the assays for
the normal donors and PNH patients. At the time of the study,
the two patients were clinically free of infection or thromboem-
bolicdisease, did not show anysigns of active hemolysis, and had
not received blood transfusions in the past 6 mo. Soluble CD14
plasma levels were measured usinga sandwich ELISA. Briefly, mi-
crotiter plates coated with 28C5 mAb were incubated with dilu-
tionsof serum or purified recombinant soluble CD14. Biotinylated
18E12 mAb wasadded anddetected usingastreptavidin-horseradish
peroxidase conjugate (Zymed Laboratories, Inc., South San Fran-
cisco, CA)ando-phenylenediamine (OPD) substrate (Sigma Chem-
ical Co.). Plates were read at 490 nm. LBP plasma levels were as-
sessed usingasimilarELISA, butinstead ofthemAbs,apolyclonal
goat anti-human LBP IgG Ab was used as capture Ab, and the
same polyclonal Ab biotinylated as the detecting Ab. Purified na-
tive human LBP was used as standard.
Endothelial Cell Activation Assay.
￿
HUVECs were plated in 96-
well microtiter plates as described (6) 2-3 d before the assay.
Confluent HUVECs were washed threetimeswith endotoxin-free
RPMI supplemented with 1 mg/mlhuman serum albumin (dilu-
tion buffer), incubated with different dilutions of E. coli 0111:B4
or S. minnesota wild-typeLPS, together with 4% normal or PNH
blood, or 2% of thecorresponding plasma. Final volume was0.2
ml/well. Experiments were done in triplicate and repeated at least
once. 18E12 mAb was added to either blood or plasma to block
CD14, and IB4mAb was used for CD18 inhibition. In other ex-
periments, hIL10 and anti-hIL10 were addedto theLPS-bloodmix-
ture. All reagents were simply mixedtogether in thewells, without
any preincubation period for the inhibitors. In one experiment,
purified neutrophils andmononuclear cellswere resuspended in di-
lution buffer at aconcentration corresponding to 4% wholeblood.
2% normal human plasma and different dilutions of 0111:B4LPS
were added to the purified cells and the mixtures were transferred
to HUVECmonolayers in 96-well plates. In anotherexperiment,
4% normal humanwholebloodwasincubatedwith differentdoses
of LPS for'6 h. Blood was then centrifuged, supernatants were
collected and incubated in parallel with 4% whole blood mixed
to the same doses of LPS as those used with whole blood. After
6-h incubation, supernatants were harvested and kept at -20°C
forIL8determination. At theendofallexperiments, the endothelial
cellswere washed five timeswith dilution buffer andVCAM-1 ex-
pressed by the HUVEC was determined by direct ELISA on the
cell surfaceusingafirst anti-hVCAM-1 mAb andasecond peroxi-
dase-conjugated goat anti-mouse Ab (6).
Whole Blood Assay.
￿
LPS activation of wholeblood was tested
using normal and PNH blood as described (15). Briefly, 250 pl
ofheparinized bloodwasincubated4.5 hin 1mlpyrogen-freepoly-
propylenetubes(Sarstedt, Inc., Sparks, NV) with 0111:B4or Re595
LPS. In some experiments hIL10 was added. At the end, blood
was resuspended using 750Al of dilution buffer (1:4 dilution) and
then centrifuged. TNF activity in supernatants was determined
using the sensitive WEHI 164 cell line clone 13-derived bioassay
(16). Typically the limit of detection of this assay is 0.25 U/ml of
TNFactivity. Resultsobtained with supernatants were multiplied
by four and expressed as TNF U/ml of whole blood (sp actof the
rhTNF standard, 5 x 10' U/mg).
Adaptation.
￿
In some experiments, we tested blood adapted to
smalldosesof0111:B4LPS. Wholenormal heparinized bloodwas
incubated with doses of LPSrangingfrom 1 pg/ml to 2.5 ng/ml
in sterile, LPS-free siliconized glass tubesfor 11 hat 37°C in 100%humid atmosphere containing 5% COz. Blood was then cen-
trifuged to collect the cells and the TNF activity in the superna-
tant plasma was measured. The collected blood cells were then
washed three times with dilution buffer and finally resuspended
by adding 1.2 volume of the cell pellet using fresh plasma from
the same donor kept at 4°C during the adaptation period. This
adaptedwholebloodwasthen challenged with LPSusingLPSdoses
ranging from 0.03 to 100 ng/ml. To obtain mock-adapted blood,
blood from the same donor was stored at 37°C, centrifuged, and
resuspended in thesame manner as adaptedblood except that addi-
tion ofLPSwasomitted. This mock-adapted bloodwaschallenged
with LPS in parallel with the adapted samples. LPS- and mock-
adapted blood were further tested for their ability to support in-
direct HUVEC activation in the presence of a challenge dose of
0111:B4 LPS.
FRCS ®Analysis.
￿
For analysis ofCD14 andCD11bsurface ex-
pression by myeloid cells, whole blood from normal donors and
PNH patients was incubated 45 min with PE-labeled anti-CD14
(MY4) and FITC-labeled anti-CD11b (IOM1) or theirisotype con-
trols.Bloodwas then washed threetimeswith PBS, pH 7.3 (Irvine
Scientific, SantaAna, CA), incubated for 2 minwith redcell lysis
buffer (Coulter Corp.), fixed, washed threemore times with PBS,
and finally resuspended in 1 ml PBSfor FRCS® analysis, according
to theprotocol ofthemanufacturer (red cell lysis kit, CoulterCorp.).
Whitebloodcells were analyzed usingtheFACScano (BectonDick-
insonImmunocytometry Systems, SanJose,CA), compensated for
dualcolors, andgatedformyeloidcells (excluding lymphocytes from
the final analysis). Percent expression of a surface marker was as-
sessed using quadrants in the two colors mode. Thresholds were
determined using the PE and FITC isotype controls. Monocytes
andneutrophils were also gatedandanalyzed separately. Anti-CD14
mAb recognizing different epitopes were used for CD14 staining
of normal andPNHbloodcells. Theseincluded 28C5, 18E12, MY4,
63D3, and UCHM1. In these experiments, we used an indirect
method with a FITC-labeled goat anti-mouse IgG second Ab.
Omission of the first Ab and isotype controls served as negative
controls, whereas anti-CD18 IB4 mAb served as positive control.
Results
Blood-dependentEnhancementofLPS-induced Endothelial Cell
Activation. We first determined the relative importance of
wholebloodcompared with plasma to support an LPS-induced
response of endothelial cells (HUVEC). As shown in Fig.
1A, in the presence ofwholeblood, 1,000-fold less LPS was
required to achieve the level of HUVEC activation (assessed
by VCAM-1 upregulation) observed with plasma alone. En-
dothelial cells coincubated with whole blood became fully
activated with picomoles of LPS, whereas nanomolar quan-
tities of LPS were needed when only plasma was present.
Substitution of blood for plasma also induced a 15-50-fold
increase in HUVEC sensitivity to LPS when IL-8 was mea-
sured (data not shown). In the absence of HUVEC, only
small amounts of IL-8 (<10%) were measured in the same
volume ofbloodstimulated with thesame range ofLPSdoses,
suggesting an endothelial cell origin for most of the IL-8
in thewholeblood experiments (datanot shown). To deter-
mine the importance of the CD14 molecule in the LPS-
dependentactivation of endothelial cells, the anti-CD14 mAb
18E12 wasaddedto plasma or bloodincubated with LPS and
HUVEC. In both experiments with plasma andwith blood,
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(A) Upregulation of VCAM-1 by HUVEC incubated 6 h
with S. minnesota wild-typeLPSin presence of4% wholeblood(O), 2%
plasma (A), 4% bloodplus 25 Wg/mlanti-CD14mAb 18E12("), or 2%
plasma plus 25 ug/ml 18E12 (A). (B) Upregulation of VCAM-1 by
HUVEC incubated 6 hwith 0111:B4 LPS in presence of purified blood
mononuclear cells (equivalent to 4% wholeblood[O]), purified neutro-
phils Q), or 2% plasma (").
LPS-induced activation of endothelial cells was strongly in-
hibited by 18E12 (Fig. 1 A). Addition ofpurified mononuclear
cells (containing monocytes) to plasma was sufficient to recon-
stitute the response noted with whole blood. In contrast,
addition of purified neutrophils to plasma had no enhancing
effect (Fig. 1 B). However, purified mononuclear cells added
to plasma did not completely restore the effect ofwholeblood.
This problem is thought to be due to the hyporesponsive-
ness of monocytes to LPS, once isolated from whole blood.
This has been a constant finding in our laboratory.
Ability ofPNHBloodto EnhanceLPSActivation ofEndothelial
Cells. To further address the question of the participation
of membrane-bound CD14 in this blood-dependent enhance-
ment ofendothelial cell sensitivity to LPS, we tested the ability
of blood from normal donors or PNH patients to cause an
upregulation of VCAM-1 in HUVECstimulated with LPS.
Typically, blood cells from PNH patients lack GPI-anchored
membrane proteins and therefore membrane CD14 is poorly
expressed if not absent (17-19). To confirm the diagnosis of
PNH in our patients and define their levelof mCD14 expres-
sion, we stained blood cells with PE-labeled anti-CD14 mAb
MY4. As shown in Fig. 2, neutrophil expression of mCD14
was absent in the first PNH patient and minimally expressed
in the second (<15% of positive cells) compared with bloodFluorescence intensity
[LPS] ng/ml
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Figure 2.
￿
FACS® analysis of neutrophils from whole blood obtained
from a normal individual and two patients with PNH incubated with
(A) PE-labeled anti-CD14 mAb MY4 (filled curves), or PE-labeled isotype
control orno Ab (unfilled curves); (B) FITC-labeled anti-CD11b mAb IOMl
(filled curves) or FITC-labeled isotype control or no Ab (unfilled curves).
from a normal donor. Similar results were obtained by gating
on the monocyte population. CD14 staining patterns were
identical when five different anti-CD14 mAbs recognizing
distinct epitopes were used (data not shown). In contrast,
CD11b (Fig. 2) and CD18 (data not shown), transmembrane
subunits of the CD11b/CD18 (MAC-1) integrin, were ex-
pressed at normal levels in PNH myeloid cells. Monocyte and
neutrophil counts in the two PNH patients were not sig-
Figure 3.
￿
Bioactive TNF-cx production in whole blood from a normal
individual (O) and two patients (" and /) with PNH incubated 4.5 h
with S. minnesota Re595 LPS.
nificantly different from normal donors. Functional studies
using blood from these patients showed that their level of
TNF production was very low in response to Re595 LPS
(Fig. 3) or 0111:B4 LPS (data not shown), compared with
normal blood. Importantly, whole blood from PNH patients
was fullyresponsive to heat-killed S. aureus, a CD14-indepen-
dent agonist for TNF productionby monocytes (3). In blood-
HUVEC coincubation experiments, the ability of PNH blood
to participate in the upregulation of VCAM-1 by HUVEC
stimulated with LPS was much lower than normal blood,
only barely distinguishable from the curves obtained with
their corresponding plasma (Fig. 4). However, plasmas from
PNH patients were as potent as normal plasma to enable
HUVEC activation by LPS, suggesting normal activity of
soluble CD14 and LBP in these plasmas (Fig. 4). Indeed, levels
of 3.8, 5 .4, and 2.2 /ig/ml of soluble CD14 were measured
in the plasma from three PNH patients (two from San Diego
and one from Seattle), as compared with 1.6, 2, and 2.8 pg/ml
in the normal donors used in these studies. Plasma LBP levels
were also comparable, 36, 19, and 12 p.g/ml for the PNH
patients and 26, 25, and 16 14g/ml in the normal donors.
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￿
Upregulation of VCAM-1 by HUVEC incubated 6 h with
S. minnesoo wild-type LPS in thepresence of4% whole blood (open symbols)
or 2% plasma (closed symbols) from a normal donor (A) and two PNH
patients (B and C).0
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Figure 5.
￿
Upregulation of VCAM-1 by HUVEC incubated 6 h with
4% whole blood (O), 2% plasma (A), 4% whole blood containing 40
ng/ml human recombinant 11,10(") or 2% plasma containing 40 ng/ml
human recombinant IL-10 (A).
Effect ofhIL-10.
￿
IL-10, produced by a variety of cells, in-
cluding T h cells and macrophages, has been described as a
deactivating substance for monocytes/macrophages (20, 21).
In experiments not shown here, hIL-10 completelyinhibited
LPS-induced TNF productionin whole human blood or by
rabbit peritoneal elicited macrophages with doses of hIL-10
as low as 20 ng/ml. To assess the importance of the cytokine
secretion by monocytes in endothelial cell activation, we in-
cubated hIL-10 with LPS, blood, and HUVEC. As shown
in Fig. 5, 40 ng/ml hIL-10 had a clear inhibitory effect, al-
though not as dramatic as anti-CD14 mAb. No further in-
hibitory effect was observed when hIL-10 levels were raised
to 1 jig/ml (data not shown). An anti-hIL-10 mAb added
to hIL-10 restored the LPS-induced acti
Table 1.
￿
Effect ofBlood Adapted to PrimaNew
Dose of LPS, and VCAM-1 Expression
After 1 ng/ml LPS challenge of whole
blood
Secondary TNF response
in whole blood (U/ml)
Decrease in TNF activity
(compared with mock-
adapted blood [%])
After 3 pg/ml LPS challenge of blood
incubated with HUVEC
Decrease in VCAM
expression in HUVEC
incubated with adapted
blood (compared with
mock-adapted blood [%])"'
" Calculated with OD 490-660 nm.
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indicating the specificity of hIL-10 effects (data not shown).
However, hIL-10 had no direct effect on LPS-induced HUVEC
activation when only plasma was present (Fig. 5).
Adaptation of Whole Blood to LPS and the Effect ofAdapta-
tion on LPS-induced Activation ofEndothelial Cells. Monocytes
and macrophages adapted to low doses of LPS become hypo-
responsive to a new challenge of LPS as assessed by TNF secre-
tion (22). We tested the ability of adapted versus mock-adapted
blood to enhance HUVEC activation. TNF activities found
after 11-h incubation of whole blood with various primary
doses of 0111:B4 LPS are shown in Table 1. After washing
and resuspension of the cell pellet in fresh plasma, adapted
blood was partially resistant to a new LPS challenge, as com-
paredwith mock-adapted blood (see Table 1) . This decrease
in TNF production in adapted bloodwas confirmed at different
doses ofchallenge LPS, ranging from 0.03 to 100 ng/ml (data
not shown). We then tested if whole adapted blood would
still enhance endothelial cell activation in response to a chal-
lenge dose of LPS. As shown in Table 1, blood adapted to
small doses of LPS was less potent than mock-adaptedblood
to coactivate HUVEC with LPS. Fig. 6 shows the ability
ofblood adapted to 2.5 ng/ml LPS, mock adapted blood and
plasma to induce activation of HUVECstimulated with LPS.
In experiments not shown here, we have determinedwhether
endothelial cells could be adapted to small doses of LPS in
presence of serum. Using IL-8 as a marker for endothelial
cell activation, no adaptation phenomenon was observed in
these cells, i.e., "adapted" and nonadapted endothelial cells
respond the same to a challenge dose of LPS.
Role ofa Soluble Factor Versus Direct Cell-Cell Interactions
ation of HUVEC, in Blood-dependent HUVECActivation by LPS. Besides
ry Doses of LPS on TNF Production in the Same Blood Challenged with a
in HUVEC Coincubated with Adapted Blood after a New Challenge Dose of LPS
my-
0 1 10 100 500 2500
(= mock adapted)
<1 <1 <1 7 34 79
47 38 23 16 8 3
19 51 66 83 94
4 21 38 45 560.5
Figure 6.
￿
Upregulation of VCAM-1 by HUVEC incubated 6 h with
various doses ofE. coli 0111:B4 LPS and 4% whole mock-adapted blood
(O), 4% whole blood preadapted for 11 h with 2.5 ng/ml 0111:B4 LPS
(") or 2% plasma (A).
eloid cell-derived soluble mediators, myeloid cell-endothelial
cell contacts through adhesion molecules might be impor-
tant for an indirect endothelial cell activation by LPS. The
CD18 subunit, part of the MAC-1, and LFA-1 integrins,plays
a critical role in the firm adhesion of myeloid cells to en-
dothelial cells (23). Anti-CD18 mAb 1134, which totally blocks
the CD18-dependent adhesion ofmyeloid cells to endothelial
cells (24), was used to address this question. IN had no in-
hibitory effect on VCAM-1 upregulation (Fig. 7) or IL-8
production (data not shown) by HUVEC, suggesting a minor
role for CD18-dependent adhesion of myeloid cells to en-
dothelial cells in LPS-induced activation of HUVEC. We then
addressed the involvement of a soluble factor(s) produced in
blood upon LPS stimulation versus a direct contact between
blood cellsand endothelial cells as the trigger of endothelial
cell activation. We found that cell-free, conditioned plasma
from blood incubated with doses of LPS in the picomolar
range was sufficient to reconstitute the level ofHUVEC ac-
tivation observed with whole blood (Fig. 8). Thus, direct
contact ofblood cells to endothelium in the presence of LPS
does not seem to be required to produce the enhancing effect.
In contrast, a stable and soluble factor(s) produced in whole
blood mediates the amplification noted with whole blood.
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Figure 7.
￿
Upregulation of VCAM-1 by HUVEC incubated 6 h with
various doses ofE. coli 0111:B4 LPS and 4% whole blood (O), 4% whole
blood containing 50 pg/ml anti-CD18 mAb IB4 (/), or 2% plasma (A).
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Figure 8.
￿
Upregulation of VCAM-1 by HUVEC incubated 6 h with
0111:B4 LPS and 4% blood (O), 2% plasma (") orwith plasma harvested
from 4% blood preincubated 6 h with 0111:B4 LPS (supemates, A).
Discussion
This work addresses the question of the relative impor-
tance of the direct and the indirect pathway for endothelial
cell activation by LPS via soluble CD14. We found that when
endothelial cellswere incubated with whole blood, they were
fully activated with picomolar doses of LPS, whereas nano-
molar quantities of LPS were required for the same level of
activation when only plasma was used. These picomolar levels
ofLPS are consistent with the levels measured in plasma from
endotoxemic or septic patients (25, 26). The first indication
of the crucial role ofCD14-bearing cells in blood to produce
this enhancement came from blockade experiments involving
anti-CD14 mAb. Indeed, endothelial responses to LPS in-
cubated with blood could be almost completely blocked by
the anti-CD14 mAb.
Another important demonstration that membrane-bound
CD14 and myeloid cells had a central role in this enhanced
sensitivity ofendothelial cells to LPS came from experiments
where blood from patients with PNH was substituted for
normal blood. PNH blood cells lack GPI-anchored proteins
because of a mutation in an enzyme critical in the early syn-
thesis ofGPI anchors (27, 28). As demonstrated in this work
and by others (18, 19), CD14 is missing or poorly expressed
in myeloid cells from PNH patients. However, normal to
elevated levels of soluble CD14 were found in the plasma of
these patients, as is the case for other GPI-linked proteins
found in soluble forms in PNH plasma (29, 30). These par-
ticular features of PNH blood gave us a unique opportunity
to test the involvement ofcell-associated CD14 in the indirect
pathway of LPS-induced endothelial cell activation. We found
that PNH blood was hyporesponsive to LPS to produce TNF.
In blood from another PNH patient, both TNF-a and IL-6,
as well as IL-8 mRNA were produced at lower than normal
levels in response to LPS (Martin, T R., University of
Washington, Seattle, WA, personal communication). These
observations reflect the poor mCD14 expression by PNH my-
eloid cells. However, the involvement ofGPI-anchored mol-
ecules other than mCD14 cannot be totally ruled out. Using
heat-killed S. aureus, a CD14-independent agonist for mono-
cyte/macrophage activation, we demonstrated that PNH blood
cells were not deficient in TNF productionper se. PNH blooddid not enhance endothelial cells activation above the level
of activation dependent on the direct pathway, i.e., depen-
dent on soluble CD14, suggesting again a crucial role for
membrane-bound CD14 and myeloid cells in this system. It
is also interesting to notice' that soluble CD14 (present in
PNH plasma) does not seem to substitute for membrane-
bound CD14, despite an interaction of sCD14 with its ligand,
LPS, in serum (6). In another system involving a GPI-anchored
receptor, the ciliary neurotopic factor (CNTF) receptor a,
soluble complexes of CNTF receptor a and its ligand (CNTF)
are as potent as the GPI-attached complex to interact with
the two other receptor complex components (LIFO and
GP130) to transduce a signal to the interior of the cell (31,
32). This does not seem to be the case for the LPS-CD14
pathway. Experiments using purified blood leukocytes allowed
us to demonstrate that the enhancing effect of whole blood
was a property of the mononuclear cell fraction, but not the
neutrophils. Because the whole blood amplification effect is
blocked with anti-CD14 mAbs and is absent in PNH blood,
we conclude that it is the monocyte that is responsible for
this effect and not the lymphocyte present in the mononuclear
fraction.
Adhesion ofmyeloid cells to endothelial cells is a complex,
multistep event involving different molecules at the surface
of both cell types. Among them, the CD18 molecule, subunit
of the MAC-1 and LFA-1 leukocyte integrins, is critical for
a firm adhesion ofneutrophils and monocytes to endothelial
cells (23). Cellular activation dependent on the adhesion pro-
cess is poorly understood. For example, it is not known if
adhesion events are quantitatively important for triggering
cells to produce proinflammatorymolecules. Using anti-CD18
mAb IB4, our data suggest that CD18-mediated adhesion
ofwhite blood cells is not important for the initial activation
of endothelial cells to upregulate VCAM-1 or produce IL-8.
Soluble mediators including cytokines released upon LPS
stimulation are very likely to participate in the activation ob-
served in endothelial .cells incubated with LPS and normal
blood (8). Supporting this point, IL-10, which inactivates
monocytes for cytokine production(20, 21), partially inhibited
the blood-dependent activation of endothelial cells. Interest-
ingly, IL-10 had no effect on endothelial cells directly acti-
vated with LPS and plasma, suggesting the absence of an
IL-10 receptor in these cells. Moreover, the evidence that the
transfer ofplasma from blood incubated with LPS is sufficient
to reproduce the enhancing effect observed with whole blood
indicates that this amplification effect is likely to be mediated
by a soluble and stable mediator(s) produced in blood. Leu-
kocyte-endothelial cell interactions are not required for the
enhancement because of the addition of whole blood.
These findings raise the question of the raison d'8tre of
the direct pathway of endothelial cell activation, involving
LBP and soluble CD14, since the indirect pathway seems to
require three orders of magnitude less LPS to achieve the same
levelof endothelial cell activation. The phenomenon ofadap-
tation of blood to LPS may indicate an answer. Since my-
eloid cells in prolonged contact with LPS become hyporespon-
sive (effect demonstrated both in vitro [22] and in vivo [33])
then, with time, the direct pathway might become impor-
tant for maintaining endothelial cell activation. Interestingly,
the magnitude of the decrease of endothelial cell activation
by LPS when incubated with adapted blood was less than
the decrease ofTNF activity in the same adapted blood chal-
lenged with LPS. This suggests that the presence of at least
one other mediator besides TNF is responsible for the LPS-
dependent indirect endothelial cell activation observed with
whole blood. The direct pathway might also play an impor-
tant role in the extravascular space. During sepsis, increased
permeability of the endothelium would allow transudation
of plasma. Epithelial cells would be activated in the presence
of LPS, LBP, and soluble CD14 to produce IL-8 (6) and up-
regulate ICAM-1 (Pugin J, , unpublished observation), a
receptor for neutrophil integrins. Thus, epithelia activated
by LPS might play an important role in the initial phase of
tissue inflammation by attracting and activating neutrophils
in situ. Finally, in a disease such as PNH where the indirect
pathwayis nonfunctional, the direct pathway of endothelial
cell activation might be crucial for an inflammatory response
to LPS.
In conclusion, we have shown that in the activation of
human endothelial cells by LPS in the presence ofblood, the
indirect pathway, involving mCD14 on monocytes, is quan-
titatively more important than the direct pathway dependent
on LBP and soluble CD14. However, whether the endothelial
cells are activated directly or indirectly, the CD14 molecule
plays a critical role. Monocyte-derived stable, soluble medi-
ators are responsible for the indirect pathway and further work
is being pursued to identify them.
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